MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5114/reum/199741

Медицинская библиотека · Reumatologia · 2025

Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.

Saidane Olfa, Bouden Selma, Jerbi Ameni, Rouached Leila, Mahmoud Ines, Tekaya Rawdha, Tekaya Aicha Ben, Abdelmoula Leila

СтатьяОбзорПеревод пока не подготовлен

Аннотация

INTRODUCTION

Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance. Interleukin-1 (IL-1) inhibitors may not yield sufficient efficacy and safety. Interleukin-6 inhibitors (tocilizumab - TCZ) have been suggested to be potentially beneficial. This systematic literature review aimed to evaluate the existing data on the efficacy and safety of IL-6 inhibitors in the treatment of FMF.

MATERIAL AND

METHODS

A systematic literature review was conducted using PubMed, Embase, Scopus, Web of Science, and the Cochrane Library to identify literature published until February 2024 on "Tocilizumab" OR "Interleukin-6 inhibitor" AND "Familial Mediterranean Fever". This study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

RESULTS

A total of 11 studies were included, corresponding to 68 patients: 6 studies were case reports, 3 were case series, and 2 were randomized control trials. Tocilizumab was indicated mainly for amyloid A (AA) amyloidosis and resistance/intolerance to other drugs. Tocilizumab showed efficacy in controlling FMF attacks and disease symptoms including fever, abdominal pain, arthritis and arthralgia. Inflammatory markers including C-reactive protein and serum amyloid A protein decreased. A decrease in proteinuria levels was reported in 20 patients. Adverse events were recorded in one-third of patients and led to TCZ discontinuation in 5 patients. No deaths associated with anti-IL-6 treatment were documented within a median follow-up period of 13 months.

CONCLUSIONS

Although the duration of follow-up of TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a good treatment option after IL-1 inhibitors and warrants further investigation.

Для цитирования: Saidane Olfa, Bouden Selma, Jerbi Ameni, Rouached Leila, Mahmoud Ines, Tekaya Rawdha, Tekaya Aicha Ben, Abdelmoula Leila. Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.. Reumatologia. 2025. DOI: 10.5114/reum/199741.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.